Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - peginterferon beta-1a - solution for injection - 188microgram/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - peginterferon beta-1a - solution for injection - 250microgram/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - nusinersen sodium - solution for injection - 2.4mg/1ml

Euroopan unioni - englanti - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiple sclerosis, relapsing-remitting - immunosuppressants - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5.1 for important information on the populations for which efficacy has been established).

Israel - englanti - Ministry of Health

vitamed pharmaceutical industries ltd - alcohol 70 %; chlorhexidine gluconate - solution - external - alcohol 70 % 70 %v/v; chlorhexidine gluconate 0.5 %w/v - chlorhexidine - chlorhexidine - disinfection of the skin, and for the cleaning of babies umbillical cords until detached.

Israel - englanti - Ministry of Health

rekah pharmaceutical industry ltd, israel - povidone-iodine - ointment - povidone-iodine 10 % - povidone-iodine - povidone-iodine - for the disinfection of skin infections and inflammations, wounds and superficial burns.

Israel - englanti - Ministry of Health

rekah pharmaceutical industry ltd, israel - povidone-iodine - solution - povidone-iodine 10 % - povidone-iodine - povidone-iodine - antiseptic for use in first aid in wounds, scratches, mild burns. for treatment of skin infections caused by bacteria or fungi.

Israel - englanti - Ministry of Health

vitamed pharmaceutical industries ltd - hydroxyethylcellulose; povidone - solution - povidone 1.65 %; hydroxyethylcellulose 0.4 % - other ophthalmologicals - artificial tears.

Euroopan unioni - englanti - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - airexar spiromax is indicated for use in adults aged 18 years and older only.asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.chronic obstructive pulmonary disease (copd)airexar spiromax is indicated for the symptomatic treatment of patients with copd, with a fev1

Euroopan unioni - englanti - EMA (European Medicines Agency)

hcs bvba  - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for further information please refer to section 5.1.